 has issued priority review vouchers to three companies developing psychedelic-based treatments, accelerating federal evaluation of emerging mental health therapies.){kind=link}
The U.S. Food and Drug Administration (FDA) has issued priority review vouchers to three companies developing psychedelic-based treatments, accelerating federal evaluation of emerging mental health therapies.
What the Vouchers Mean
The vouchers require the FDA to review eligible drug applications within 60 days, significantly shortening the typical approval timeline. The move is part of a broader push to explore new treatments for conditions that are often difficult to manage.
Drugs Under Study
The companies are researching:
- Psilocybin for treatment-resistant depression and major depressive disorder
- Methylone, a synthetic compound related to MDMA, for post-traumatic stress disorder (PTSD)
Additionally, the FDA approved an early-stage clinical trial of noribogaine hydrochloride, a derivative of ibogaine, for potential treatment of alcohol use disorder—marking the first U.S.-based study of its kind.
Federal Push for Psychedelic Research
The announcement follows an executive order signed by Donald Trump directing federal agencies to speed up research and review of psychedelic therapies. The goal is to address rising rates of depression, PTSD, and addiction.
Promise and Caution
Early studies suggest psychedelic-assisted therapy may offer lasting mental health benefits when administered in controlled settings. However, none of these drugs are currently approved for routine psychiatric use in the U.S.
Many remain classified as Schedule I substances, indicating a high potential for abuse and no officially accepted medical use. Experts stress that further research is needed to confirm safety and effectiveness.
What’s Next
The FDA says it will soon release updated guidance for companies developing psychedelic treatments, including recommendations on clinical trial design and patient monitoring.
As interest grows, regulators emphasize balancing innovation with rigorous scientific standards to ensure patient safety.
For more on this story, stay tuned to Que Onda Magazine.